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OBJECTIVE: To compare the incremental cost-utility
ratio (ICUR) of latanoprost and travoprost versus timolol
in France. METHOD: The probability to develop a visual
ﬁeld defect (VFD) was issued from a double-masked
double-dummy, phase III multi-centre clinical trial com-
paring travoprost 0.004% od, latanoprost 0.005% od
and timolol 0.5% bid, using the 2 discriminant functions
(stable and progressive patients) published by Stewart,
1993. A Markov model was constructed to reproduce the
cost and utility of a patient treated over ﬁve years, includ-
ing the following states: VFD and no VFD. Utility was
derived from Brown (2000), based on visual acuity. Direct
medical and indirect costs were estimated from a ﬁve-year
retrospective patient chart analysis. Both costs and out-
comes were discounted at a 5% rate. The economic per-
spective was the one of Society. Sensitivity analysis was
performed on the 25th to 75th percentile range of the dis-
criminant empirical distribution function. RESULTS: The
ICUR of latanoprost over timolol was €20,327/QALY
and €15,374 for travoprost. Results without discounting
were similar, €20,150 and €15,196, respectively. At the
25th percentile of the discriminant function, the ICUR
were €58,250 and €38,428 respectively and €11,262 
and €11,639 at the 75th percentile. At the median of 
the distribution function, travoprost in comparison to
latanoprost brings 0.01 QALY at a €51 additional cost.
CONCLUSION: According to our model, travoprost is a
cost-effective alternative to timolol. The additional cost
to be paid for one QALY in comparison to timolol is
lower with travoprost than with latanoprost.
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OBJECTIVE: To improve patient reported outcomes of
brimonidine 0.2% ophthalmic solution, a new formula-
tion was researched and developed. The intent was to
improve patient satisfaction and patient comfort while
maintaining patient efﬁcacy. The economic impact of
these improvements was also evaluated. METHODS:
Randomized, controlled trials were conducted in 743
patients to evaluate the original formulation vs. the new
formulation. The new formulation reduced the concen-
tration of the active ingredient from 0.2% to 0.15% and
replaced the preservative, benzalkonium chloride (BAK),
with Purite. Patient outcomes were satisfaction and
comfort level with the product. The economic evaluation
model estimated the annual cost per patient including
pharmacy and medical ofﬁce visits (including those that
may occur due to adverse events.) RESULTS: More
patients were satisﬁed with the new formulation (83%)
than the original (75%) (p < 0.05). 85% of patients
reported the new formulation was comfortable vs. 79%
for the original. Approximately 90% of the new formu-
lation patients had no reported ocular allergy vs. 84% of
the original formulation patients. Considering the addi-
tional costs associated with allergy as an additional ofﬁce
visit, the economic model estimated the cost of an allergy
patient was 36% higher than for an allergy free patient.
CONCLUSION: Patients receiving the new 0.15% refor-
mulation of brimonidine rated their treatment satisfaction
and comfort level higher than patients on the original for-
mulation while experiencing the same level of efﬁcacy.
The estimated cost savings for allergy-free patients could
have a positive impact on medical budgets.
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OBJECTIVES: High-dose vitamin supplementation
(HDVS) has recently been demonstrated to be of beneﬁt
for the prevention of progression of age-related macular
degeneration (AMD) by the investigators of the Age-
Related Eye Disease Study (AREDS), a National Eye 
Institute-sponsored randomized clinical trial. The aim of
our study was to determine the cost-utility of HDVS 
in patients with the moderately advanced form of “dry”
AMD. The analysis was performed from the perspective
of a third party-insurer who was considering adding
HDVS to their list of insured beneﬁts. METHODS:
Various decision analyses, based on Markov processing,
were performed. Our models incorporated published data
from the AREDS, our own patient-based utilities 
(n = 127) and anticipated reductions in the need for treat-
ments and services needed to treat the “wet” form of this
disease. In addition, we created a cost-utility model by
considering incremental medical costs incurred through
the use of HDVS. Various sensitivity analyses were
carried out to determine the robustness of our models.
RESULTS: Our decision analysis, based on patient-
derived utilities, demonstrated that HDVS with both
antioxidants and zinc was found to be the preferred
method of action, as it was associated with an expected
relative gain in utility of 2.9 percent. Monte Carlo simu-
lation demonstrated that the observed difference between
treatment and placebo was statistically signiﬁcant (p =
0.021). Our cost-effective model, which employed a 5%
discount rate, demonstrated that the cost per quality-
of-life adjusted year (QALY) associated with high dose
vitamin supplementation, when applied to patients with
the moderately advanced form of dry age-related macular
degeneration (group 3 or 4 disease according to the
AREDS), was $2,816.63. CONCLUSION: High-dose
vitamin supplementation of patients with the moderately
advanced form of “dry” age-related macular degenera-
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tion can be considered to be a very cost-effective strategy
when used to prevent progression of AMD.
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OBJECTIVES: To estimate disability pension costs and
institutionalisation associated with low visual acuity
(LVA) and blindness in France. METHODS: Two
national surveys performed by INSEE (Institut National
de la Statistique et des Etudes Economiques) on disabil-
ity and institutionalisation in France (1998–1999) were
carried out. Information (socio-demographics, disability
reasons, disability pension and type of institution) was
collected on two national representative samples of living
at home and institutionalised populations. Three groups
were identiﬁed in each case: blind people, LVA people and
a control group (non-blind/LVA general population).
Linear regression was used to adjust the group pension
differences for gender, age and professional categories.
The probability of being institutionalised due to blind-
ness/LVA when >55 was estimated with Bayesian rules.
RESULTS: 15,288 people were included in the survey of
institutionalised persons; 279 were blind and 2,536 had
LVA. The control group included more women. The blind
were younger while those with LVA were older; the blind
had fewer jobs. 16,915 people were included in the living
at home survey; 86 were blind and 1,080 had LVA. The
control group had more women and was younger, while
those with LVA had less skilled jobs. Disability pensions
varied with gender, age and professional categories. Insti-
tutionalised blind people received €112.64 per month
more than the control group and €484.33 more than
people living at home. Figures for LVA patients were
respectively €19.22 and €201.52. Probability of being
institutionalised was 6.13% for blind people, 5.91% for
LVA and 1.14% for the control group. A person has a 5.4
times greater chance of being institutionalised if blind and
5.2 times with LVA. CONCLUSION: Blindness and LVA
lead to additional disability pensions payments and insti-
tutionalisation. Medical programs aimed at delaying
blindness or LVA may have economic consequences
outside the direct medical costs that should be taken into
account.
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OBJECTIVES: To assess cost-effectiveness and cost-
utility ratios of a new anti-allergic agent Olopatadine in
comparison to the reference treatment, Levocabastine, 
in Seasonal Allergic Conjunctivitis (SAC) in France,
Germany, Italy, Spain, Sweden and the United Kingdom.
METHODS: Data from a randomized, double-blind clin-
ical trial of Olopatadine (O) versus Levocabastine (L) in
SAC were used in the analysis. A total of 210 patients
were randomized (O:101, L:109). Ocular symptoms 
and investigator’s Clinical Global Impression (CGI) were
reported at baseline and at days 7, 14, 30 and 42. Fac-
torial analysis techniques were used to derive a synthetic
symptoms score (effectiveness score) from multi-
dimensional symptom scales. In order to transform symp-
toms scores into utility scores, a panel of 32 ophthal-
mologists was interviewed in the 6 European countries to
collect data on the painfulness of various symptomatic
statuses. Curves representing the evolution of effective-
ness and utility scores over time were projected from 42
to 90 days, assuming 3 types of treatment effects after day
42, namely, a maintained effect (H1), a catch-up on com-
paritor (H2) and no additional effect (H3). Areas under
effectiveness and utility curves (AUCs) were computed in
both arms. Olopatadine-Levocabastine differentials were
respectively represented in the effectiveness criterion as
the number of Symptoms Adjusted Days saved, (SAD)
and in the utility criterion as the number of Quality
Adjusted Days saved, (QAD). RESULTS: Olopatadine
showed a gain from 1.3 (H3) to 2.3 (H1) SADs, and from
0.8 (H3, UK) to 4.2 (H1, Germany) QADs, over 3
months. Assuming a 20% higher price for Olopatadine
compared to Levocabastine, the incremental cost-
effectiveness ratios of Olopatadine ranged from €1.27
(H1, France) to €21.3 (H3, Italy) per SAD saved, while
incremental cost-utility ratio ranged from €1.06 to €23.4
per QAD saved. CONCLUSION: Olopatadine showed
reasonable cost-effectiveness and cost-utility ratios versus
Levocabastine in the treatment of SAC for 6 European
countries.
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OBJECTIVES: The objective of the study is to investigate
the cost-effectiveness of treating patients with psoriasis
vulgaris in Sweden. METHODS: The cost-effectiveness
analysis was performed by comparing effectiveness data
obtained from an international multicentre study with the
cost of the two products. RESULTS: The expected cost
per percentage reduction in PASI in Sweden is SEK 15.78
for TCP twice daily, followed by SEK 8.98 for cal-
cipotriol, and TCP once daily SEK 8.29 when comparing
